Atila BioSystems
- Company typePrivate
- Founded2009
- HeadquartersMountain View, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Atila BioSystems firmographics
Firmographics- Name
- Atila BioSystems
- Legal name
- Atila BioSystems
- Website
- https://atilabiosystems.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Atila BioSystems industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where Atila BioSystems is headquartered
LocationHeadquarters
- HQ city
- Mountain View
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Atila BioSystems business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Instrument Sales: Sale of PCR instruments including iAMP Automatic Instrument, iAMP Personal Station Real-Time PCR System, Power-Gene 9600 Plus Real-Time PCR System, and Nucleic Acid Extraction Systems.
- Diagnostic Kits and Assays: Sale of diagnostic assay kits including infectious disease panels, cancer detection kits, blood screening assays, NIPT kits, and drug resistance assays. Products sold as RUO (Research Use Only) or CE-IVD certified.
- Master Mixes and Reagents: Sale of amplification master mixes including Digital PCR Mastermix, Bst Isothermal Universal Mastermix, and Hotstart Taq Universal PCR Mastermix for research purposes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | NGS Library Preparation Kits - priced per unit |
| Unit Pricing | Pay-as-you-go | NIPT Testing Kits - various pricing tiers |
| Other | Multi-year contract | Bulk/Enterprise Pricing - quote-based |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Atila BioSystems product offering
Product offeringCore offering
Atila BioSystems develops and manufactures proprietary molecular diagnostic kits, reagents, and PCR instruments for clinical laboratories and healthcare providers. Its catalog of over 100 assays spans infectious disease multiplex panels (respiratory, sepsis, wound, STI, UTI, meningitis), HPV screening and genotyping, NIPT for aneuploidy screening, digital PCR cancer mutation panels, NGS library preparation kits, blood screening assays, and antimicrobial resistance detection, all built on patented extraction-free isothermal amplification chemistries (3N, Omega, iAMP) and supported by dedicated real-time PCR and nucleic acid extraction instruments.
Product overview
Atila BioSystems is a molecular diagnostics company founded in 2009 offering a comprehensive portfolio of over 100 assays for clinical diagnostic applications. The company operates on a platform-plus-products model anchored by proprietary extraction-free isothermal amplification technologies including 3N Technology (for ultra-high multiplex capability) and Omega Nucleic Acid Amplification (patented isothermal technology for signal generation and speed). The core product family includes: the iAMP technology platform for extraction-free molecular testing across infectious diseases (respiratory, sexually transmitted infections, gastrointestinal, wound, urinary tract, blood stream), antimicrobial resistance, and sepsis; the AmpFire platform for HPV screening and genotyping; the ScreenFire HPV RS assay for cervical cancer screening; the iSAFE NIPT system for non-invasive prenatal testing; and digital PCR (dPCR) products for cancer mutation screening (EGFR, KRAS, BRAF, NRAS, HER2, TP53, PIK3CA, RET/MET, BRCA1/2) and blood screening (HIV, HBV, HCV, sickle cell disease). The portfolio spans across NGS library preparation for cancer panels, prenatal/reproductive health testing, blood donor screening, antimicrobial resistance detection, and general PCR/LAMP master mixes. The company also offers dedicated instruments including the iAMP Automatic Instrument (fully automated), iAMP Personal Station Real-Time PCR System, Power-Gene 9600 Plus Real-Time PCR System, and automated nucleic acid extraction systems. The BioDome format (Universal and Zebra BioDome) provides novel strip/plate configurations with pre-loaded reagents for simplified workflows.
Differentiator
Problem solved
Functional benefit
Brands
- BioDome: A product platform for molecular diagnostics panels, including Universal BioDome and Zebra BioDome formats.
- iAMP
- AmpFire
- iSAFE
- ScreenFire
- OPENCI
Products and services
- iAMP Respiratory Panel
Quantifiable outcome
- iAMP Respiratory Panel delivers results in under 90 minutes with extraction-free workflow
- +4 more outcomes
Companies that use Atila BioSystems
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Atila BioSystems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration13 records
Feature5 records
Atila BioSystems partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Rotary InternationalcoreAtila BioSystems' AmpFire HPV testing technology has been included in Rotary's global initiative for expanding access to cervical cancer screening. This partnership supports Rotary's efforts to combat cervical cancer in underserved regions worldwide through Atila's rapid, affordable molecular diagnostics.
Scale indicators4 records
Atila BioSystems competitors and assessment
Company assessmentBroad incumbents
- Bio-Rad Laboratories: Bio-Rad is an established life-science-tools and diagnostics company with major qPCR and digital-PCR platforms, reagents, and assay-enabling products. It is both a technology comparator and an incumbent platform on which many Atila assays run.
- QIAGEN: QIAGEN is a broad molecular-diagnostics and life-science-tools incumbent with qPCR, digital-PCR, sample-preparation, assay, and instrument offerings. It directly overlaps Atila in nucleic-acid workflows, HPV and prenatal testing, and laboratory instrument platforms.
Direct peers
- GenMark Diagnostics: GenMark Diagnostics, now part of Roche, provides sample-to-answer multiplex molecular testing through the ePlex system. Its syndromic panels and integrated instrument workflow are highly comparable to Atila's rapid multiplex iAMP approach.
- Meridian Bioscience: Meridian Bioscience develops molecular diagnostic assays, reagents, and immunoassay products for infectious disease and other clinical applications. Its menu-based testing model and laboratory customer base closely match Atila's diagnostic-kit business.
- Molbio Diagnostics: Molbio Diagnostics offers Truenat molecular point-of-care testing with an integrated instrument and assay menu. Its focus on resource-limited settings and rapid decentralized diagnostics is closely comparable to Atila's global-health positioning.
- OptiGene: OptiGene develops isothermal nucleic-acid amplification instruments, chemistries, and molecular detection products. Its amplification technology and instrument-plus-assay model closely parallel Atila's iAMP and related platforms.
- QuidelOrtho: QuidelOrtho develops and commercializes molecular diagnostic assays and instruments across respiratory, infectious disease, and other testing categories. Its integrated test-and-instrument model directly competes with Atila's assay-plus-PCR-instrument offering.
- Cepheid: Cepheid is a direct molecular-diagnostics peer known for the GeneXpert sample-to-answer system and PCR tests for infectious disease. It competes for laboratories and healthcare providers seeking rapid, minimally complex molecular workflows.
- Seegene: Seegene specializes in multiplex syndromic molecular diagnostics using real-time PCR. Its multi-pathogen panels, clinical laboratories focus, and multiplexing-led differentiation closely resemble Atila's iAMP panel strategy.
Emerging players
- LumiraDx: LumiraDx develops integrated point-of-care molecular and immunoassay systems designed to simplify testing near patients. Its focus on compact instruments and rapid sample-to-answer workflows partially overlaps Atila's portable iAMP offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Atila BioSystems compliance and trust
Trust signalCompliance4 records
Atila BioSystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Atila BioSystems leadership team
Management profileNumber of profiles
Atila BioSystems funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Atila BioSystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Atila BioSystems
What does Atila BioSystems do?
Atila BioSystems develops and manufactures proprietary molecular diagnostic kits, reagents, and PCR instruments for clinical laboratories and healthcare providers. Its catalog of over 100 assays spans infectious disease multiplex panels (respiratory, sepsis, wound, STI, UTI, meningitis), HPV screening and genotyping, NIPT for aneuploidy screening, digital PCR cancer mutation panels, NGS library preparation kits, blood screening assays, and antimicrobial resistance detection, all built on patented extraction-free isothermal amplification chemistries (3N, Omega, iAMP) and supported by dedicated real-time PCR and nucleic acid extraction instruments.
Is Atila BioSystems a public or private company?
Atila BioSystems is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Atila BioSystems founded?
Atila BioSystems was founded in 2009. It employs 11 to 50 people.
Where is Atila BioSystems based?
Atila BioSystems is headquartered in Mountain View, United States, in the North America region.
How does Atila BioSystems make money?
Three revenue lines are on record. Instrument Sales are the primary driver. The others are diagnostic Kits and Assays and master Mixes and Reagents.
Who are Atila BioSystems's main competitors?
Broad incumbents on record are Bio-Rad Laboratories and QIAGEN. Direct peers are GenMark Diagnostics, Meridian Bioscience, Molbio Diagnostics, OptiGene, QuidelOrtho, Cepheid and Seegene. LumiraDx is listed as an emerging player.
Does Atila BioSystems have an API?
No public API is recorded for Atila BioSystems.
What industry is Atila BioSystems in?
Atila BioSystems's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.